solution squirted on face; Vial leak; Pharmaceutical product complaint; This non-serious case was reported by a nurse via call center representative and described the occurrence of occupational exposure via skin contact with product in a female patient who received Herpes zoster (Shingrix) (batch number K72R2, expiry date 24-JAN-2026) for prophylaxis. This case was associated with a product complaint. On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced occupational exposure via skin contact with product (Verbatim: solution squirted on face), product leakage (Verbatim: Vial leak) and pharmaceutical product complaint (Verbatim: Pharmaceutical product complaint). The outcome of the occupational exposure via skin contact with product, product leakage and pharmaceutical product complaint were unknown. Additional Information: GSK Receipt Date: 27-DEC-2024 The nurse stated she attempted to insert needle into adjuvant component of Shingrix and the needle bounced off the rubber stopper and the solution squirted onto the health care professional face, which led occupational exposure via skin contact with product.. The reporter something was wrong with the stopper on that vial as she used another adjuvant and was able to successfully withdraw the medication. The patient did receive the dose of Shingrix using another adjuvant vial. The nurse refused to send a picture stating she does not have time to do so. The information received from QA department on 22-JAN-2025 GlaxoSmithKline had completed its investigation for the quality defect that was reported. The investigation included a review of the defect trends and testing of the retained samples and a review of the related production records, all of which demonstrated that the reported batch was produced in compliance with the applicable procedures and met all required specifications. Nothing atypical was identified while the product was under GlaxoSmithKline control which would explain the reported quality defect. The GlaxoSmithKline considered the complaint that was the object of this report as unsubstantiated.